Pulmokine Overview
- Founded
-
2007
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
- Investors
-
3
Pulmokine General Information
Description
Developer of biopharmaceutical therapies designed to treat pulmonary arterial hypertension (PAH) and related disorders. The company's pulmonary disease and kinase inhibitor technology treats crucial lung conditions, enabling patients suffering from lung diseases to access pulmonary drugs.
Contact Information
Website
www.pulmokine.net
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
- 7 University Place
- Room B127
- Rensselaer, NY 12144
- United States
+1 (518) 000-0000
Pulmokine Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Secondary Transaction - Private | 000 | Completed | Generating Revenue | |||
| 5. Grant | 01-Jan-2017 | 00000 | 000 | Completed | Generating Revenue | |
| 4. Grant | 01-Jan-2016 | 00.000 | 000 | Completed | Generating Revenue | |
| 3. Seed Round | 04-Mar-2015 | 000 | 000 | Completed | Generating Revenue | |
| 2. Debt - General | 01-Oct-2014 | Completed | Generating Revenue | |||
| 1. Grant | 27-Mar-2014 | $1.5M | Completed | Generating Revenue |
Pulmokine Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of biopharmaceutical therapies designed to treat pulmonary arterial hypertension (PAH) and related disorders.
Biotechnology
Rensselaer, NY
000
000000 - 000
000
0000 0
r adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad min
0000 000000000
Austin, TX
00
As of 0000
000.00
0000000000 0
000.00
000000
p ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dol
0000000000000
Mechelen, Belgium
0000
As of 0000
00.000
000000000
00.000
Add Comparison
Pulmokine Competitors (17)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lung Therapeutics | Venture Capital-Backed | Austin, TX | 00 | 000.00 | 0000000000 0 | 000.00 |
| 000000000 (0000000 | Formerly VC-backed | Mechelen, Belgium | 0000 | 00.000 | 000000000 | 00.000 |
| 000000 000000 | Accelerator/Incubator Backed | Morristown, NJ | 0 | 00.000 | 000000000 | 00.000 |
| 00000000 000000000 | Venture Capital-Backed | Tucson, AZ | 0 | 000.00 | 00000000000 | 000.00 |
| 000000000 00000000 | Corporation | Pasadena, CA | 000 | 00.000 | 000000 - 000 | 00.000 |
Pulmokine Patents
Pulmokine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210038510-A1 | Formulations of kinase inhibitors and prostanoids | Pending | 08-Feb-2018 | 0000000000 | |
| EP-3532063-A4 | Combination therapy for treating pulmonary hypertension | Pending | 27-Oct-2016 | 0000000000 | 0 |
| US-10231966-B2 | Combination therapy for treating pulmonary hypertension | Active | 27-Oct-2016 | 0000000000 | 00 |
| CA-3041679-A1 | Combination therapy for treating pulmonary hypertension | Pending | 27-Oct-2016 | 0000000000 | |
| EP-3532063-A1 | Combination therapy for treating pulmonary hypertension | Pending | 27-Oct-2016 | A61K31/497 |
Pulmokine Executive Team (5)
Pulmokine Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Shreefal Mehta Ph.D | Self | Board Director | 000 0000 |
Pulmokine Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | ||
| National Heart, Lung and Blood Institute | Government | 000 0000 | 000000 0 | ||
| National Institutes of Health | Government | 000 0000 | 000000 0 |